GlassScriptPhysician profile
John Y Chung
NPI 1710943709
$6,483.91
in general payments reported to CMS, 2019-2025
32 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,409 · 2020: $342 · 2021: $175 · 2022: $586 · 2023: $450 · 2024: $804 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,972.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,262.00 | 2019 | |
| Merz North America, INC. | $1,074.83 | 2019 | |
| Abbvie INC. | $947.04 | 2019-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $481.18 | 2019-2025 | |
| Lilly USA, LLC | $402.62 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $344.01 | 2019-2025 | Libtayo, Dupixent |
| Mimedx Group, INC. | $274.17 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $208.22 | 2019-2024 | |
| Janssen Biotech, INC. | $197.24 | 2019-2025 | Simponi, Simponi Aria, Stelara |
| Pfizer INC. | $176.58 | 2019-2022 | |
| Strata Skin Sciences, INC. | $126.26 | 2019-2025 | Xtrac |
| Allergan, INC. | $125.75 | 2020-2021 | |
| Genzyme Corporation | $117.19 | 2022-2025 | |
| Ucb, INC. | $104.19 | 2019-2024 | Bimzelx |
| Leo Pharma INC. | $101.56 | 2019-2025 | Adbry |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $101.16 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.30 | 2019-2025 | Cabtreo, Jublia |
| Genentech USA, INC. | $47.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.43 | 2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $36.87 | 2019 | |
| Paratek Pharmaceuticals, INC. | $35.20 | 2025 | Nuzyra |
| Aclaris Therapeutics, INC. | $24.21 | 2019 | |
| Organogenesis INC. | $23.50 | 2025 | Via Matrix |
| Epi Health, LLC | $17.16 | 2022 | |
| Dermavant Sciences, INC. | $16.51 | 2023 | Vtama |
| Medline Industries LP | $15.46 | 2020 | |
| Boston Scientific Corporation | $15.45 | 2021 | |
| Amgen INC. | $15.00 | 2021 | |
| Medtronic Vascular, INC. | $14.89 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.51 | 2023 | |
| Glenmark Therapeutics INC. | $3.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.